Reports
Organoids and Spheroids Market Trends Analysis Report, 2026-2034
REPORT DETAILS
Report Code:
PM1782
No. of Pages:
116
Format:
PDF
Published Date:
Base Year:
2025
Author:
Shreyas Shirsat
Historical Data:
2021-2024
REPORT DETAILS
Report Code:
PM1782
Published Date:
No. of Pages:
116
Historical Data:
2021-2024
Format:
PDF
Author:
Shreyas Shirsat
Base Year:
2025
ABOUT THIS REPORT
Organoids and Spheroids Market Share, Size, Trends, Industry Analysis Report – By Type (Organoids and Spheroids), Application, End Use, and Region; Segment Forecasts, 2026–2034
What is Organoids and Spheroids Market Size?
The organoids and spheroids market size was valued at USD 2.14 billion in 2025 and is anticipated to exhibit a CAGR of 23.3% during the forecast period. The growth is driven by rising demand for personalized medicine and increase in investment in stem cell research.
Key Takeaways
- In 2025, North America had the biggest share of the organoids and spheroids market, with 44.85%. This was because of strong biotech research and advanced healthcare infrastructure.
- The U.S. made up about 80% of the regional market in 2025. This was due to high spending on research and development and a large number of biotech and pharmaceutical companies.
- Asia Pacific is expected to grow at the fastest rate, 24% per year, because biotech research is growing and healthcare spending is increasing too.
- The organoids segment held the largest share of 59.65% in 2025, due to its strong ability to replicate human organ functions for research and drug testing.
- The developmental biology segment led with a 30.17% share. This was because it was widely used to study how tissues and organs form.
Market Statistics
- 2025 Market Size: USD 2.14 Billion
- 2034 Projected Market Size: USD 13.99 Billion
- CAGR (2026–2034): 23.3%
- North America: Largest Market Share in 2025
To Understand More About this Research: Download Sample Report
Organoids and Spheroids Market Overview
The organoids and spheroids market is experiencing significant growth due to the increasing demand for advanced 3D cell culture technologies in research and drug development. Organoids and spheroids are three-dimensional cell structures that mimic the architecture and functionality of real tissues and organs, making them valuable tools for studying complex biological processes. 3D technologies are widely used in disease modeling, regenerative medicine, personalized medicine, and drug discovery since they provide more accurate and reliable data compared to traditional 2D cell cultures. The market is driven by advancements in stem cell research, a growing focus on precision medicine, and the increasing adoption of organoid-based models by pharmaceutical companies for drug screening and toxicity testing. Additionally, the rising prevalence of chronic diseases such as cancer has fueled the demand for sophisticated models, further propelling market growth. Also, many players in the market are launching products that is driving the market revenue. For instance, in April 2024, ACRO Biosystems introduced a 3D organoid bioprocess development platform to accelerate the development of bio-therapeutics.
Organoids and Spheroids Market Growth Factors
Advancements in Stem Cell Research
Rapid advancements in stem cell research, particularly with induced pluripotent stem cells (iPSCs), make it easier to generate organoids that mimic human tissues, which drives the organoids and spheroids market. iPSC-derived organoids are invaluable for disease modeling, replicating the genetic and cellular characteristics of specific patients, which enhances personalized medicine approaches. These organoids are increasingly used in regenerative medicine for tissue repair and replacement. Additionally, combining iPSC research with CRISPR gene-editing technology allows for the creation of more precise disease models, enabling researchers to understand the impact of genetic mutations. This progress in stem cell technology has led to greater adoption of organoids in academic research, clinical applications, and pharmaceutical development, expanding the market rapidly.
In May 2023, Roche opened the Institute of Human Biology (IHB) in Basel, Switzerland, to drive research in human model systems, specifically organoids that are human stem cell-derived. The IHB aims to unite human biology researchers, scientists, and bioengineers from academia and industry to investigate human biology.
Increased Application in Drug Discovery and Personalized Medicine
There is a rising application of organoids and spheroids in drug discovery and personalized medicine. These 3D cell culture models closely mimic human tissue architecture and function, providing more accurate and predictive data for drug screening and toxicity testing compared to traditional 2D cultures. Pharmaceutical companies are leveraging organoids to identify potential drug candidates, assess their efficacy, and reduce the likelihood of late-stage clinical failures. Additionally, organoids derived from patient-specific cells enable personalized treatment approaches, allowing for the testing of drug responses on an individual basis, thereby improving treatment outcomes and reducing adverse effects. This growing adoption in precision medicine is fueling the expansion of the organoids and spheroids market.
In March 2024, Sinai Health's USD 10 million investment will create an innovative tissue engineering platform for producing organoids to help in disease research and drug discovery. It features advanced equipment that complements current technology at the Lunenfeld-Tanenbaum Research Institute.
Restraining Factors
High Cost of Development and Production
The high cost of developing and producing organoids and spheroids is a significant barrier for the market. Creating and maintaining these complex 3D cell culture systems requires advanced technologies, skilled personnel, and specialized equipment, all of which contribute to high operational expenses. Generating organoids, especially from induced pluripotent stem cells (iPSCs), is labor-intensive and time-consuming, further increasing costs. These financial barriers limit accessibility, especially for smaller research institutions and companies with limited budgets, which hinders the widespread adoption of organoid-based models in research and drug development.
Report Segmentation
The organoids and spheroids market is primarily segmented on the basis of type, application, end use, and region.
|
By Type |
By Application |
By End Use |
By Region |
|
Organoids
|
|
|
|
By Type Insights
Spheroids Segment Accounted for Larger Market Share in 2025
In 2025, the spheroids segment dominated the organoids and spheroids market due to their cost-effectiveness, ease of production, and broad applications in drug discovery and cancer research. Spheroids are simpler and less expensive to create than organoids, making them a practical choice for various applications, including high-throughput drug screening and studying tumor microenvironments. Spheroids are versatile, as they can be formed from different cell types and are valuable in modeling tumors and assessing drug responses, contributing to their significant market share and widespread adoption in pharmaceutical research.
The organoids segment is expected to experience significant growth in the organoids and spheroids market during the forecast period as it can simulate disease occurrence and enable custom drug approaches. According to a published article by Nature, scientific studies suggest that organoids are 3-D structures that mimic organs and are utilized to study human organ development in the absence of human embryos. The ability to replicate organ-level complexity in vitro allows for accurate modeling of diseases and drug responses, provides new tools for developing targeted therapies, and reduces reliance on animal models.
By Application Insights
Developmental Biology Segment Accounted for Largest Market Share in 2025
The developmental biology segment held a significant share of the global organoids and spheroids market in 2025 due to the increasing use of these advanced culture systems to study human developmental processes. Organoids are derived from induced pluripotent stem cells (iPSCs) and embryonic stem cells and provide valuable insights into embryogenesis, tissue development, and genetic inheritance. Moreover, Organoids are widely used to model and study the development of various organs, such as the brain, stomach, and pancreas, by mimicking important signaling pathways, including BMP, FGF, and WNT. The ability to replicate and analyze developmental mechanisms with high accuracy contributes to the substantial revenue share of the developmental biology segment. The depth of understanding gained through these models drives their widespread use and investment in developmental biology research, establishing it as a dominant application in the market.
The regenerative medicine segment is experiencing substantial growth in the organoids and spheroids market due to their superior ability to replicate human organ functionality compared to animal models. These three-dimensional cell culture models show promise for pharmaceutical research, disease modeling, personalized medicine, and regenerative therapies. Hubrecht Organoid Technology (HUB), a leader in this field, has developed various organoid models that replicate human tissues such as the intestine and liver. These 3D models are utilized in drug discovery and regenerative medicine to understand disease mechanisms better and to test potential therapies more effectively than traditional animal models.
By End Use
In 2025, the biotechnology and pharmaceutical companies segment dominated the organoids and spheroids market due to the increasing interest of pharmaceutical start-ups in leveraging organoids and spheroids for potential clinical applications. Additionally, the widespread use of these 3D cell cultures in preclinical drug discovery and development processes, especially for testing drug efficacy and toxicity, significantly contributes to the growth of this segment. Their ability to mimic human tissue environments allows pharmaceutical entities to enhance drug screening and reduce the time required for clinical trials. Thus, the biotechnology and pharmaceutical companies segment remains a dominant force in the organoids and spheroids market.
Organoids and Spheroids Market Regional Insights
North America Dominated Global Organoids and Spheroids Market in 2025
By region, the study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America dominated the organoids and spheroids market due to the increasing adoption of 3D cell culture technologies and the rising use of organoids and spheroids for personalized medicine and drug discovery. Additionally, the presence of leading biotechnology firms and prestigious research institutions in countries accelerates technological advancements. Companies such as Organovo and academic institutions such as Harvard University and the University of Toronto are at the forefront of research in organoids and spheroids. For instance, in February 2024, Cell Microsystems partnered with OMNI Life Science to bring the innovative products CERO, CASY, & TIGR in the region to support spheroid and organoid research.
Asia Pacific is expected to be the fastest-growing region in the organoids and spheroids market. The regional market growth is attributed to advances in regenerative medicine, research funding, and personalized medications. In October 2022, AIM Biotech launched the organiX System, a lab tool to closely model human disease by adding vascularization and immune competence to organoids, spheroids, and tumor biopsies.
Global Regulatory Landscape for Organoid and Spheroid-Based Therapies and 3D In Vitro Models
United States (FDA)
|
Aspect |
Key regulatory elements relevant to organoids/spheroids |
Description |
|
Overall framework |
Organoid‑based therapies (e.g., transplanted organoids) generally fall under FDA’s framework for regenerative medicine products, including human cells, tissues, and cellular and tissue‑based products (HCT/Ps) and related biologics regulations. |
FDA describes a risk‑based, flexible framework for regenerative medicine products, including cellular and gene therapies and tissue‑engineered products. CBER’s standards program for regenerative medicine therapies (SRP‑RMT) supports standards for complex cell‑based products. |
|
Expedited programs for organoid‑based regenerative therapies |
Regenerative medicine therapies using organoids may be eligible for Regenerative Medicine Advanced Therapy (RMAT) designation and other expedited programs if they treat serious or life‑threatening conditions. |
FDA guidance on expedited programs for regenerative medicine therapies outlines RMAT, Breakthrough Therapy and other expedited programs for qualifying cell‑based and tissue‑engineered products. |
|
Use of organoids/spheroids in non‑clinical safety (non‑animal methods) |
3D organoid and spheroid models are recognized as part of the broader move toward alternative non‑animal methods in preclinical safety, especially after the FDA Modernization Act 2.0, which allows non‑animal tests as acceptable evidence for certain toxicity assessments. |
A 2024 framework on 3D cell‑culture toxicity testing notes that FDA Modernization Act 2.0 allows non‑animal data such as 3D models and chips in preclinical safety assessment, emphasizing their role as complementary evidence. |
|
General non‑clinical guidance (ICH adoption) |
FDA applies ICH M3(R2) on non‑clinical safety studies, which explicitly encourages validation and use of new in vitro alternative methods once accepted by ICH authorities, covering organoid/spheroid models when validated. |
ICH M3(R2), adopted by FDA, states that new in vitro alternative methods for safety evaluation may replace current standard methods once validated and accepted by all ICH regulators. |
European Union (EMA / EU system)
|
Aspect |
Key regulatory elements relevant to organoids/spheroids |
Description |
|
Advanced therapy medicinal products (ATMPs) |
Organoid‑based therapeutic products are generally regulated as ATMPs (e.g., tissue‑engineered products) under Regulation (EC) No 1394/2007 when used for treatment, prevention, or diagnosis in humans. |
EMA’s ATMP framework explains that human cells and tissues, including tissue‑engineered products, fall under Regulation 1394/2007, with the Committee for Advanced Therapies (CAT) classifying such products. A review of ATMPs discusses the regulation’s goals and risk profile for advanced cell/tissue therapies. |
|
Classification and scientific advice |
The CAT issues product classification opinions and scientific advice for advanced therapies, which can include organoid‑based cell or tissue products. |
EMA notes that CAT has classified multiple stem‑cell–containing medicines as ATMPs and provides advice on development pathways and classification. |
|
Acceptance of 3D in vitro models in non‑clinical testing |
EMA, as an ICH partner, applies ICH M3(R2) and supports validated in vitro alternatives, including 3D organoid and microphysiological systems, especially for organ‑specific toxicity (e.g., liver, kidney, cardiac). |
The 3D toxicity‑testing framework highlights that EMA supports 3D data in regulatory submissions, particularly for organ‑specific toxicity models. ICH M3(R2), hosted by EMA, encourages adoption of validated alternative in vitro methods. |
Japan (MHLW / PMDA)
|
Aspect |
Key regulatory elements relevant to organoids/spheroids |
Description |
|
Regenerative medicine legal framework |
Organoid‑based cell and tissue products are regulated under Japan’s Pharmaceutical and Medical Device Act and the Act on the Safety of Regenerative Medicine, which categorize cellular and tissue‑based products by risk level and provide a conditional, time‑limited approval system. |
An overview of Japan’s regenerative medicine policies states that cellular and tissue‑based products are classified under the Pharmaceutical and Medical Device Act and the Act on the Safety of Regenerative Medicine, with three risk categories and conditional approvals for promising therapies. PMDA documents describe “regenerative medical products” and associated guidelines on quality and safety. |
|
Regulatory authorities |
The Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) are the main regulators for regenerative medical products, including organoid‑based therapies. |
Japan’s policies specify MHLW and PMDA as the primary authorities overseeing cellular and tissue‑based products within regenerative medicine. |
|
Support for 3D data in toxicology |
Similar to EMA and FDA, PMDA is reported to support 3D organoid data (e.g., liver, kidney, cardiac models) as part of toxicity evaluation when scientifically justified. |
The 3D toxicity‑testing framework notes that PMDA supports 3D data in regulatory submissions for organ‑specific toxicity, alongside EMA and FDA. |
OECD / ICH and Cross‑Regional Testing Frameworks
|
Aspect |
Key regulatory elements relevant to organoids/spheroids |
Description |
|
OECD Test Guidelines (TGs) and new in vitro methods |
OECD’s Test Guidelines Programme is progressively expanding to recognize alternative in vitro methods for chemical hazard testing; current TGs are mainly for 2D or simpler 3D systems, and recent analyses note that no formal TG yet exists specifically for organoids, but work is ongoing. |
OECD documents describe work on test guidelines that allow assessment of skin and eye irritation, corrosion and sensitization using alternative in vitro methods. A 2025 review on human organoids for environmental‑contaminant toxicity states that no OECD Test Guideline currently exists specifically for organoids, although organoid‑based assays are under discussion. |
|
ICH guidance on non‑clinical safety (M3(R2)) |
ICH M3(R2) provides harmonized guidance across US, EU and Japan for non‑clinical safety studies, explicitly allowing new in vitro alternative methods (including advanced 3D cultures) to replace standard methods once they are validated and accepted by all ICH authorities. |
The ICH M3(R2) guideline states that new in vitro alternative methods for safety evaluation, once validated and accepted, can replace current standard non‑clinical methods, supporting the future regulatory use of organoid and spheroid systems. |
|
Broader 3R / animal‑replacement policy context |
All major regions (through ICH and OECD frameworks) emphasize reduction, refinement and replacement (3R) of animal testing, which underpins regulatory interest in organoid and spheroid models as possible replacements or refinements. |
ICH M3(R2) highlights reduction in animal use and notes that new validated alternatives can be used in place of animal studies. OECD’s Test Guidelines work promotes alternative methods for several toxicity endpoints, aligning with 3R principles. |
Key Market Players and Competitive Insights
Strategic Initiatives by Market Players to Drive Competition
The competitive landscape of the organoids and spheroids market is characterized by a diverse range of global and regional players competing to capture market share through innovation, strategic partnerships, and geographic expansion. Key companies such as Thermo Fisher Scientific, Corning Incorporated, and Merck KGaA are actively pursuing market leadership by focusing on innovation and forming strategic alliances. These organizations prioritize product development, enhancing safety, functionality, and cost-efficiency to meet the industry's evolving needs. Common competitive strategies include mergers and acquisitions. Other notable players in this market include 3D Biomatrix, 3D Biotek LLC, AMS Biotechnology (Europe) Limited, Cellesce Ltd., Greiner Bio-One, Hubrecht Organoid Technology (HUB), InSphero, Lonza, Prellis Biologics, CytoSMART, and STEMCELL Technologies Inc.
TheWell Bioscience, a Biotechnology company based in North Brunswick Township, New Jersey, introduced the VitroGel Organoid Recovery Solution, a new cell harvesting solution that can recover organoids and cells faster and more efficiently. It can dissociate animal-based ECM in just 2 minutes and complete the entire cell harvesting process in 15 minutes, compared to over 60 minutes with the leading solution in the market. This solution is designed to rapidly harvest high-quality intact organoids with high yields for various applications.
Thermo Fisher Scientific, an America-based life sciences and clinical research company, launched Gibco Human Plasma-like Medium (HPLM) in March 2021. The product is the first cell culture medium available that mimics the metabolic profile of human plasma, providing researchers with a more realistic representation of cell growth within the human body. Gibco HPLM mimics the salt concentrations and over 60 polar metabolites found in human plasma, which allows researchers to study physiologically relevant environments in disease research such as cancer. When supplemented with fetal bovine serum (FBS), it supports cell growth and viability similar to conventional media without requiring adaptation for most cell lines.
Major Players Operating in Global Organoids and Spheroids Market
- 3D Biomatrix
- 3D Biotek LLC
- AMS Biotechnology Limited
- Cellesce Ltd.
- TheWell Bioscience
- Greiner Bio-One
- Hubrecht Organoid Technology (HUB)
- InSphero
- Lonza
- Merck KGaA
- Prellis Biologics
- STEMCELL Technologies Inc.
- Thermo Fisher Scientific, Inc.
Recent Developments in the Industry
- 2026: International Conference Alerts lists many organoid-related conferences and events around the world in 2026. These events serve as a convergence point for researchers, scientists, and industry professionals, offering a platform to discuss the latest advancements in drug development, 3D cell culture techniques, and tissue modeling. (Source: International Conference Alerts)
- In November 2026, Shenzhen will host Organoids & Organs-on-Chips Asia 2026. This gathering will unite researchers, businesses, and technology firms focused on organoids, 3D cell culture, and organ-on-chip systems. The event's core purpose is to foster innovation, facilitate networking, and advance drug discovery and biomedical research. (Source:Select Biosciences)
- In July 2023, Molecular Devices launched a custom organoid line expansion service, leveraging proprietary bioreactor technology to produce high-quality, assay-ready organoids for drug discovery.
- In February 2024, ATCC & Tissue Dynamics collaborated under the BIRD Foundation to develop advanced cardiac organoid-based kits for improved cardiac safety testing in drug development.
Report Coverage
The organoids and spheroids market report emphasizes key regions across the globe to provide a better understanding of the product to the users. Also, the report provides market insights into recent developments and trends and analyzes the technologies that are gaining traction around the globe. Furthermore, it covers an in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides a detailed analysis of the market while focusing on various key aspects such as competitive analysis, type, application, end use, and their futuristic growth opportunities.
Organoids and Spheroids Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2025 |
USD 2.14 billion |
| Market Size in 2026 | USD 2.62 billion |
|
Revenue Forecast by 2034 |
USD 13.99 billion |
|
CAGR |
23.3% from 2026 to 2034 |
|
Base Year |
2025 |
|
Historical Data |
2021–2024 |
|
Forecast Period |
2026–2034 |
|
Quantitative Units |
Revenue in USD billion and CAGR from 2026 to 2034 |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global organoids and spheroids market size was valued at USD 2.14 billion in 2025 and is projected to grow to USD 13.99 billion by 2034.
The global market is projected to register a CAGR of 23.3% during the forecast period.
North America accounted for the largest share of the global market due to the increased adoption of 3D cell culture technologies and the rising use of organoids and spheroids for personalized medicine and drug discovery.
A few key players in the market are 3D Biomatrix; 3D Biotek LLC; AMS Biotechnology (Europe) Limited; Cellesce Ltd.; Corning Incorporated; Greiner Bio-One; Hubrecht Organoid Technology (HUB); InSphero; Lonza; Merck KGaA; Prellis Biologics; CytoSMART; STEMCELL Technologies Inc.; and Thermo Fisher Scientific, Inc.
The biotechnology and pharmaceutical companies segment accounted for the largest market due to the increasing interest of pharmaceutical start-ups in leveraging organoids and spheroids for potential clinical applications.
Page last updated on: Jan-2023
Download Sample Report of Organoids and Spheroids Market
Please fill out the form to request a customized copy of the research report.
